AR118085A1 - Inhibidores de enzimas - Google Patents

Inhibidores de enzimas

Info

Publication number
AR118085A1
AR118085A1 ARP200100399A ARP200100399A AR118085A1 AR 118085 A1 AR118085 A1 AR 118085A1 AR P200100399 A ARP200100399 A AR P200100399A AR P200100399 A ARP200100399 A AR P200100399A AR 118085 A1 AR118085 A1 AR 118085A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
halo
alkoxy
alkyl
independently selected
Prior art date
Application number
ARP200100399A
Other languages
English (en)
Spanish (es)
Inventor
Xuezheng Yang
Joseph William Wrigglesworth
Alun John Smith
Smith Colin Peter Sambrook
Rachael Pittaway
Iain Robert Miller
Matthew Robert Conroy
Thomas Matthew Baker
Terence Aaron Panchal
Stefano Levanto
Karamjit Singh Jandu
Paul Stuart Hinchliffe
Julie Nicole Hamblin
Erica Lee Goldsmith
Emanuela Gancia
Andrew Peter Cridland
David Edward Clark
Michael John Stocks
David Philip Rooker
Alicja Stela Obara
Alessandro Mazzacani
Sally Louise Marsh
Simon Teanby Hodgson
David Michael Evans
Hannah Joy Edwards
Rebecca Louise Davie
Mitchell Lewis Childs
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of AR118085A1 publication Critical patent/AR118085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP200100399A 2019-08-21 2020-02-13 Inhibidores de enzimas AR118085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2019/052359 WO2021032936A1 (en) 2019-08-21 2019-08-21 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
AR118085A1 true AR118085A1 (es) 2021-09-15

Family

ID=67777359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100399A AR118085A1 (es) 2019-08-21 2020-02-13 Inhibidores de enzimas

Country Status (15)

Country Link
US (1) US20220363668A1 (cg-RX-API-DMAC10.html)
EP (1) EP4017587A1 (cg-RX-API-DMAC10.html)
JP (1) JP7566870B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220051207A (cg-RX-API-DMAC10.html)
CN (1) CN114269430A (cg-RX-API-DMAC10.html)
AR (1) AR118085A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020333222A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022000936A2 (cg-RX-API-DMAC10.html)
CA (1) CA3147228A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022000266A2 (cg-RX-API-DMAC10.html)
IL (1) IL289783A (cg-RX-API-DMAC10.html)
MX (1) MX2022002069A (cg-RX-API-DMAC10.html)
PH (1) PH12022550078A1 (cg-RX-API-DMAC10.html)
TW (1) TW202115033A (cg-RX-API-DMAC10.html)
WO (2) WO2021032936A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4017850A1 (en) * 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
WO2015171527A1 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
CA3025810A1 (en) 2016-05-23 2017-11-30 Manish P. PONDA Aminoacylindazole immunomodulators for treatment of autoimmune diseases
US10875851B2 (en) 2016-11-18 2020-12-29 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
WO2018093716A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
CN111670034A (zh) 2017-11-29 2020-09-15 洛克菲勒大学 用于治疗自身免疫性疾病的吡喃并吡唑类和吡唑并吡啶类免疫调节剂
EP4017850A1 (en) 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors

Also Published As

Publication number Publication date
JP7566870B2 (ja) 2024-10-15
MX2022002069A (es) 2022-03-17
PH12022550078A1 (en) 2022-11-21
US20220363668A1 (en) 2022-11-17
AU2020333222A1 (en) 2022-02-24
CA3147228A1 (en) 2021-02-25
CO2022000266A2 (es) 2022-01-28
TW202115033A (zh) 2021-04-16
KR20220051207A (ko) 2022-04-26
WO2021032937A1 (en) 2021-02-25
JP2022545158A (ja) 2022-10-26
IL289783A (en) 2022-03-01
BR112022000936A2 (pt) 2022-03-08
CN114269430A (zh) 2022-04-01
EP4017587A1 (en) 2022-06-29
WO2021032936A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
AR118084A1 (es) Inhibidores de enzimas
AR118083A1 (es) Inhibidores de enzimas
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR122019A2 (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
AR123848A1 (es) Compuestos espiro heterocíclicos y métodos de uso
AR118081A1 (es) Inhibidores de enzimas
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
AR107694A1 (es) Heteroarilos inhibidores de pad4
MX9300256A (es) Derivados de acido acetico y proceso para su preparacion.
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
ES2058292T3 (es) Derivados de indol.
AR106472A1 (es) Inhibidores de acc y usos de los mismos
ES2111169T3 (es) Dicetopiperazinas farmaceuticamente activas.
AR092288A1 (es) Ligandos del receptor ep1
AR105122A1 (es) INHIBIDORES DE METALO-b-LACTAMASA
CO6190523A2 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
ES2094653T3 (es) Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña.
CR7865A (es) Derivados de dihidropiranoindol -3,4-diona sustituidos y derivados de 2-hidroximetilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador del plasminogeno 1(pai-1)
ES2072003T3 (es) Medio fluidocristalino.
AR112168A1 (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
PE20240652A1 (es) Compuestos que inhiben la isoforma alfa de pi3k y metodos para tratar el cancer
AR062405A1 (es) Derivados de isoindol
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal